Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.9 SEK | +2.67% | +7.10% | +9.31% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.31% | 53.01M | B | ||
+3.37% | 69.25B | A | ||
+12.55% | 9B | A- | ||
-12.75% | 4.96B | A- | ||
+42.38% | 4.47B | - | ||
+5.23% | 3.9B | B- | ||
+19.83% | 2.45B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ORX Stock
- Ratings Orexo AB